文献速递乳腺胸部CTMR乳腺X线

使用对比增强光子计数探测器CT对乳腺癌及区域淋巴结进行分期:准确性及对患者管理的潜在影响

Staging of breast cancer in the breast and regional lymph nodes using contrast-enhanced photon-counting detector CT: accuracy and potential impact on patient management.
PubMed 文献 · Br J Radiol · 2024-01-01

前瞻性纳入13例活检证实乳腺癌并接受分期乳腺MRI的成年女性,行三相光子计数探测器CT(平扫超高分辨率及延迟50秒、180秒两期增强),与MRI和数字乳腺X线对照。PCD-CT对原发灶、转移淋巴结、多灶/多中心病变及活检后残余可疑钙化的检出与MRI结果相似,并额外发现1枚5 mm胸椎转移灶;作者认为在特定病例中可能替代乳腺MRI。

要点

  • 三相PCD-CT可显示乳腺癌原发灶的肿块或非肿块强化,与MRI所见相似。
  • 转移性淋巴结在PCD-CT上呈与原发性病灶相似的早期明显强化。
  • 超高分辨率PCD-CT可检出活检后残余可疑钙化,5例中检出4例。

核心结论

  • 三相PCD-CT扫描方案在表征乳腺癌及区域淋巴结病变方面与MRI相似,显示出初步有希望的结果,并在80%的病例中检出微小钙化;PCD-CT的超高分辨率和光谱能力可能实现对乳腺癌的全面表征,并可能成为特定病例中乳腺MRI的替代选择。

研究设计与样本

  • 前瞻性研究,纳入13例活检证实乳腺癌并接受分期乳腺MRI的成年女性(平均年龄53岁,范围36-75岁),行三相PCD-CT(平扫超高分辨率扫描及静脉注射对比剂后50秒和180秒两期增强扫描),以动态乳腺MRI和数字乳腺X线为参考标准,由三名乳腺放射科医生比较CT特征。

关键影像表现/征象

  • 13例中11例在PCD-CT上显示与MRI对应的可疑肿块或非肿块强化。
  • 3例转移性淋巴结病变均显示与原发性病灶相似的早期明显强化。
  • MRI显示多灶或多中心病变的3例均被PCD-CT识别,包括1个4 mm可疑卫星病灶。
  • 乳腺X线显示活检后残余可疑钙化的5例中4例在超高分辨率PCD-CT平扫上检出。
  • 因PCD-CT视野增大,检出1枚5 mm胸椎转移灶,而乳腺MRI未检出。

临床应用与阅片要点

  • 作者认为PCD-CT的超高分辨率和光谱能力可能实现对乳腺癌的全面表征。
  • 作者认为在特定病例中PCD-CT可能成为乳腺MRI的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To describe the feasibility and evaluate the performance of multiphasic photon-counting detector (PCD) CT for detecting breast cancer and nodal metastases with correlative dynamic breast MRI and digital mammography as the reference standard.

METHODS: Adult females with biopsy-proven breast cancer undergoing staging breast MRI were prospectively recruited to undergo a multiphasic PCD-CT using a 3-phase protocol: a non-contrast ultra-high-resolution (UHR) scan and 2 intravenous contrast-enhanced scans with 50 and 180 s delay. Three breast radiologists compared CT characteristics of the index malignancy, regional lymphadenopathy, and extramammary findings to MRI.

RESULTS: Thirteen patients underwent both an MRI and PCD-CT (mean age: 53 years, range: 36-75 years). Eleven of thirteen cases demonstrated suspicious mass or non-mass enhancement on PCD-CT when compared to MRI. All cases with metastatic lymphadenopathy (3/3 cases) demonstrated early avid enhancement similar to the index malignancy. All cases with multifocal or multicentric disease on MRI were also identified on PCD-CT (3/3 cases), including a 4 mm suspicious satellite lesion. Four of five patients with residual suspicious post-biopsy calcifications on mammograms were detected on the UHR PCD-CT scan. Owing to increased field-of-view at PCD-CT, a 5 mm thoracic vertebral metastasis was identified at PCD-CT and not with the breast MRI.

CONCLUSIONS: A 3-phase PCD-CT scan protocol shows initial promising results in characterizing breast cancer and regional lymphadenopathy similar to MRI and detects microcalcifications in 80% of cases.

ADVANCES IN KNOWLEDGE: UHR and spectral capabilities of PCD-CT may allow for comprehensive characterization of breast cancer and may represent an alternative to breast MRI in select cases.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Yalon M, Sae-Kho T, Khanna A, et al. Staging of breast cancer in the breast and regional lymph nodes using contrast-enhanced photon-counting detector CT: accuracy and potential impact on patient management. Br J Radiol. 2024. PMID: 38263843. doi:10.1093/bjr/tqad042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。